-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Equities Analysts Issue Forecasts for PureTech Health Plc's FY2022 Earnings (NASDAQ:PRTC)
Equities Analysts Issue Forecasts for PureTech Health Plc's FY2022 Earnings (NASDAQ:PRTC)
PureTech Health plc (NASDAQ:PRTC – Get Rating) – Stock analysts at Jefferies Financial Group issued their FY2022 EPS estimates for shares of PureTech Health in a report issued on Thursday, October 13th. Jefferies Financial Group analyst P. Welford expects that the company will post earnings of ($4.00) per share for the year. The consensus estimate for PureTech Health's current full-year earnings is ($3.66) per share. Jefferies Financial Group also issued estimates for PureTech Health's FY2023 earnings at ($5.00) EPS, FY2024 earnings at ($5.00) EPS, FY2025 earnings at ($6.00) EPS and FY2026 earnings at ($6.00) EPS.
Get PureTech Health alerts:Separately, Piper Sandler upped their price target on shares of PureTech Health from $37.00 to $44.00 and gave the company an "overweight" rating in a report on Thursday, August 25th.
PureTech Health Stock Performance
Shares of PRTC opened at $26.54 on Monday. The firm has a 50 day moving average price of $27.90 and a 200-day moving average price of $24.84. PureTech Health has a fifty-two week low of $18.15 and a fifty-two week high of $52.50.Institutional Investors Weigh In On PureTech Health
An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. raised its stake in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the quarter. AWM Investment Company Inc. owned approximately 2.32% of PureTech Health worth $2,513,000 at the end of the most recent reporting period. 2.32% of the stock is owned by institutional investors and hedge funds.
PureTech Health Company Profile
(Get Rating)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
See Also
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
- This Mid Cap Energy Stock is a 10-Bagger...And May Not Be Done
- Should You Make a Reservation in Marriott International Stock?
- The Outperforming Software Stock No One is Talking About
- Will Goldman Sachs' Earnings & Revenue Beats Lift Sector Higher?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
PureTech Health plc (NASDAQ:PRTC – Get Rating) – Stock analysts at Jefferies Financial Group issued their FY2022 EPS estimates for shares of PureTech Health in a report issued on Thursday, October 13th. Jefferies Financial Group analyst P. Welford expects that the company will post earnings of ($4.00) per share for the year. The consensus estimate for PureTech Health's current full-year earnings is ($3.66) per share. Jefferies Financial Group also issued estimates for PureTech Health's FY2023 earnings at ($5.00) EPS, FY2024 earnings at ($5.00) EPS, FY2025 earnings at ($6.00) EPS and FY2026 earnings at ($6.00) EPS.
PureTech Health plc(纳斯达克代码:PRTC-GET Rating)-杰富瑞金融集团的股票分析师在10月13日星期四发布的一份报告中发布了他们对PureTech Health股票2022财年每股收益的估计。杰富瑞金融集团分析师P.Welford预计,该公司今年的每股收益将达到4.00美元。对PureTech Health目前全年收益的普遍预期为每股3.66美元。杰富瑞金融集团还发布了对PureTech Health 2023财年每股收益为5.00美元、2024财年每股收益为5.00美元、2025财年每股收益为6.00美元和2026财年每股收益为6.00美元的预期。
Separately, Piper Sandler upped their price target on shares of PureTech Health from $37.00 to $44.00 and gave the company an "overweight" rating in a report on Thursday, August 25th.
另外,派珀·桑德勒在8月25日周四的一份报告中将PureTech Health的目标价从37.00美元上调至44.00美元,并给予该公司“增持”评级。
PureTech Health Stock Performance
PureTech Health股票表现
Institutional Investors Weigh In On PureTech Health
机构投资者看好PureTech Health
An institutional investor recently raised its position in PureTech Health stock. AWM Investment Company Inc. raised its stake in shares of PureTech Health plc (NASDAQ:PRTC – Get Rating) by 2,100.0% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 660,000 shares of the company's stock after purchasing an additional 630,000 shares during the quarter. AWM Investment Company Inc. owned approximately 2.32% of PureTech Health worth $2,513,000 at the end of the most recent reporting period. 2.32% of the stock is owned by institutional investors and hedge funds.
一家机构投资者最近提高了对PureTech Health股票的头寸。AWM Investment Company Inc.在提交给美国证券交易委员会的最近一份13F文件中称,该公司在第二季度将其在PureTech Health plc(纳斯达克代码:PRTC-GET Rating)的持股比例提高了2,100.0%。该公司在本季度额外购买了63万股后,拥有66万股该公司股票。在最近一个报告期结束时,AWM投资公司拥有PureTech Health公司约2.32%的股份,价值251.3万美元。2.32%的股票由机构投资者和对冲基金持有。
PureTech Health Company Profile
PureTech Health公司简介
(Get Rating)
(获取评级)
PureTech Health plc, a clinical-stage biotherapeutics company, discovers, develops, and commercializes medicines for inflammatory, fibrotic and immunological, intractable cancers, lymphatic and gastrointestinal, neurological and neuropsychological, and other diseases in the United States. The company offers KarXT targeting muscarinic acetylcholine receptors to treat schizophrenia and psychosis in Alzheimer's disease; a regenerative biology platform for androgenetic alopecia, epithelial ageing, and other medical conditions; an immunomodulation platform to treat chronic and acute inflammatory disorders; oral therapies based on defined consortia of bacteria is isolated from the human microbiome; and therapies to treat cognitive dysfunction associated with depression, multiple sclerosis, post COVID and ICU, and cancer related conditions.
PureTech Health plc是一家临床阶段的生物治疗公司,在美国发现、开发和销售治疗炎症、纤维化和免疫、顽固性癌症、淋巴和胃肠道、神经和神经心理以及其他疾病的药物。该公司提供靶向M胆碱乙酰胆碱受体的KarXT,用于治疗阿尔茨海默病的精神分裂症和精神病;用于治疗雄激素性脱发、上皮老化和其他疾病的再生生物学平台;用于治疗慢性和急性炎症性疾病的免疫调节平台;用于从人体微生物群中分离出基于特定细菌群的口服疗法;以及用于治疗与抑郁症、多发性硬化症、COVID后和ICU以及癌症相关疾病相关的认知功能障碍的疗法。
See Also
另请参阅
- Get a free copy of the StockNews.com research report on PureTech Health (PRTC)
- Does J&J Have Enough Alpha to Be a Solid Low Beta Stock?
- This Mid Cap Energy Stock is a 10-Bagger...And May Not Be Done
- Should You Make a Reservation in Marriott International Stock?
- The Outperforming Software Stock No One is Talking About
- Will Goldman Sachs' Earnings & Revenue Beats Lift Sector Higher?
- 免费获取StockNews.com关于PureTech Health(PRTC)的研究报告
- 强生是否有足够的阿尔法成为稳定的低贝塔股票?
- 这只中型股能源股是一只10-Bagger……可能做不到
- 您需要在万豪国际酒店预订吗?
- 没有人谈论的表现优异的软件类股
- 高盛的收益和收入超出预期会提振板块走高吗?
Receive News & Ratings for PureTech Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PureTech Health and related companies with MarketBeat.com's FREE daily email newsletter.
获得PureTech HealthDaily的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对PureTech Health和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧